Biotech

All Articles

Lilly encounters stage 2 failing of tau-targeting med

.The confetti is still soaring coming from Eli Lilly's event commemorating the approval of Alzheimer...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our summary of notable management hirings, shootings and...

Lykos will definitely inquire FDA to reconsider its decision observing rejection of MDMA treatment for post-traumatic stress disorder

.Observing a bad showing for Lykos Rehabs' MDMA prospect for trauma at a recent FDA advising board a...

AN 2 halves head count, stops stage 3 trial after data disappoint

.AN2 Rehabs is reassessing its company in reaction to poor midphase records, pledging to give up hal...

Merck spends $700M for bispecific, snooping autoimmune opening and also possibility to test Amgen in cancer

.Merck &amp Co. is spending $700 thousand in advance to challenge Amgen in a blood stream cancer cel...

Gilead pays out J&ampJ $320M to exit licensing package for seladelpar

.Along With Gilead Sciences almost an FDA decision for its own liver condition medicine seladelpar, ...

' All hands on deck' at Lilly as peers target excessive weight market

.Chief executive officer David Ricks can observe the business setting up tents at basecamp responsib...

Entero laying off workers, abandoning office and pausing R&ampD

.Mattress Liquidators has actually switched Entero Therapies white as a sheet. The creditor got Ente...

Exelixis falls ADC after choosing it's no match for Tivdak

.Exelixis is giving up on its cells aspect (TF)- targeting antibody-drug conjugate after ending the ...

Relay loses interest in SHP2 prevention after Genentech leaves

.3 weeks after Roche's Genentech unit walked away from an SHP2 inhibitor deal, Relay Therapeutics ha...